scholarly journals Survival Outcomes of Patients With Mediastinal Germ Cell Tumors: Experience of a Cancer Center in South America

2022 ◽  
Vol 11 ◽  
Author(s):  
Camilo Vallejo-Yepes ◽  
Carlos Andrés Carvajal-Fierro ◽  
Ricardo Brugés-Maya ◽  
Julian Beltrán ◽  
Ricardo Buitrago ◽  
...  
Keyword(s):  
South America ◽  
Germ Cell ◽  
Germ Cell Tumors ◽  
Cancer Center ◽  
Survival Outcomes ◽  
Poor Survival ◽  
First Line ◽  
Survival Prognosis ◽  
Line Chemotherapy ◽  
Mediastinal Germ Cell Tumors

PurposeMediastinal germ cell tumors (GCT) are rare neoplasms associated with poor survival prognosis. Due to their low incidence, limited information is available about this disease in South America. The objective of this study is to report the clinical characteristics and outcomes of patients with mediastinal GCT in a cancer center in Colombia.Materials and MethodsWe conducted a retrospective analysis of patients with mediastinal GCT treated at the National Cancer Institute at Bogota (Colombia) between 2008 and 2020. Survival curves were presented using the Kaplan–Meier method. Chi-square and Cox proportional hazard model tests were used for data analysis.ResultsSixty-one patients were included in the study. Of them, 60 were male and 51 (83.6%) of whom had non-seminomatous germ cell tumors (NSGCT). Twenty-nine patients (47.5%) presented with superior vena cava syndrome, and 18 (29.5%) patients had extrapulmonary metastatic involvement. The three-year overall survival (OS) of NSGCT patients was 26%. The 3-year OS of NSGCT patients who underwent surgical resection of residual mediastinal mass after chemotherapy was 59%. Non-surgical management after first-line chemotherapy was associated with a worse survival prognosis in NSGCT patients (p = 0.002). Ten patients with mediastinal seminomatous germ cell tumors (SCGT) achieved a 3-year OS of 100%.ConclusionMediastinal NSGCT had poor outcomes. Surgery of the residual mass after first-line chemotherapy seems to improve the outcome of NSGCT patients. Advanced disease at presentation may reflect inadequate access to reference cancer centers in Colombia and potentially explain poor survival outcomes in this cohort. On the other hand, mediastinal SCGT is a biologically different disease; most patients will achieve disease remission and long-term survival with first-line chemotherapy.

scholarly journals Survival outcomes for men with mediastinal germ-cell tumors: The University of Texas M. D. Anderson Cancer Center experience

2012 ◽  
Vol 30 (6) ◽  
pp. 879-885 ◽  
Author(s):  
Alan J. Rodney ◽  
Nizar M. Tannir ◽  
Arlene O. Siefker-Radtke ◽  
Ping Liu ◽  
Garrett L. Walsh ◽  
...  
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumors ◽  
Cancer Center ◽  
Survival Outcomes ◽  
University Of Texas ◽  
The University ◽  
Mediastinal Germ Cell Tumors

First-line chemotherapy of non-seminomatous germ cell tumors(NSGCTs)

2009 ◽  
Vol 35 (7) ◽  
pp. 563-569 ◽  
Author(s):  
K. Pliarchopoulou ◽  
D. Pectasides
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumors ◽  
First Line ◽  
Line Chemotherapy

Clinical outcome of postchemotherapy salvage surgery for metastatic germ cell tumors in Japan

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14654-14654
Author(s):  
K. Kakimoto ◽  
T. Kinouchi ◽  
Y. Ono ◽  
N. Meguro ◽  
O. Maeda ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Germ Cell ◽  
Salvage Surgery ◽  
Mature Teratoma ◽  
Germ Cell Tumors ◽  
Salvage Chemotherapy ◽  
Retroperitoneal Lymph Node Dissection ◽  
First Line ◽  
Residual Cancer ◽  
Line Chemotherapy

14654 Background: Salvage surgery including retroperitoneal lymph node dissection (RPLND) following chemotherapy has been considered a critical component in the comprehensive management of advanced germ cell tumors (GCT). The objectives of this study were to determine the pathologic findings and clinical outcome of patients with metastatic GCT who underwent postchemotherapy salvage surgery. Methods: From 1980 to 2004, 157 patients with metastatic diseases underwent postchemotherapy salvage surgery at three institutions. Surgical resection was indicated in the presence of residual radiographic abnormalities. The cause-specific survival rate was calculated using the Kaplan-Meier method. Results: The histology of GCT was pure seminoma in 49 patients and non-seminoma in 108 patients. As first-line chemotherapy, 30 patients were treated with PVB (cisplatin, vinblastine and bleomycin) regimen, 107 patients with PEB (cisplatin, etoposide and bleomycin) regimen and 20 patients with other regimens. Salvage surgery was performed after first-line chemotherapy in 87 patients and after salvage chemotherapy in 70 patients. As salvage surgery, RPLND was performed in 135 patients, resection of pulmonary metastasis in 38, hepatotomy in 2 and resection of metastatic brain tumors in 3. The pathological findings at surgery were necrosis in 87 (55%) patients, mature teratoma in 34 (22%) and residual cancer in 36 (23%). Five of 36 patients with residual cancer performed salvage surgery in the state of marker positive. Of the 31 patients who had residual cancer with normalized marker, salvage surgery was performed after salvage chemotherapy in 11 patients. The sites of residual cancer were retroperitoneal lymph nodes in 34 patients, lung in 4, brain in 2 and liver in 1. The cause-specific 5-year survival rates for patients who had necrosis, mature teratoma and residual cancer were 95%, 96% and 68%, respectively. Conclusions: Residual cancer could not reliably be predicted or discriminated from necrosis or mature teratoma. Therefore, salvage surgery to remove postchemotherapy residual masses remains essential in the successful treatment of metastatic GCT. No significant financial relationships to disclose.

First-Line Chemotherapy of Disseminated Germ Cell Tumors

2011 ◽  
Vol 25 (3) ◽  
pp. 543-556 ◽  
Author(s):  
Craig Nichols ◽  
Christian Kollmannsberger
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumors ◽  
First Line ◽  
Line Chemotherapy

Thoracic surgery of residual masses after first-line chemotherapy in patients with testicular (T) or primary retroperitoneal (PR) non seminomatous germ cell tumors (NSGCT)

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14563-14563
Author(s):  
A. Flechon ◽  
N. Noel ◽  
M. Rivoire ◽  
F. Mithieux ◽  
J. Droz
Keyword(s):  
Thoracic Surgery ◽  
Lung Metastases ◽  
Mediastinal Lymph Node ◽  
Germ Cell Tumors ◽  
Complete Response ◽  
Cancer Center ◽  
Thoracic Disease ◽  
First Line ◽  
Residual Masses ◽  
Line Chemotherapy

14563 Background: Exeresis of all post-chemotherapy residual masses is the standard initial treatment of T and PR NSGCT patients. The aim of the study was to analyse the surgical procedure of thoracic exeresis of residual masses in patients receiving chemotherapy in a single cancer center. Methods: We reviewed the clinical, surgical and histological charts of 143 T or RP NSGCT patients operated on between 01/01/93 and 31/12/2003. All patients had initially at least one thoracic site (lung metastases and/or mediastinal lymph node involvement). We reviewed the indications for surgery according to the size, number of lung metastases and localization of mediastinal lymph nodes. Outcome criteria were relative risk (RR) of relapse and death. Median time of follow-up was 41 months (range 4–140). Results: After first-line chemotherapy, 43 patients (30%) obtained a thoracic complete response, and 100 had thoracic residual masses (70 PR markers -, 24 PR markers +, 2 SD, 4 PD).Thoracic surgery was performed in 32 patients (25 RP-, 4 RP+, 2 SD, 1 PD) by 14 different surgeons. Among these 32 patients, 26 had less than 10 pulmonary lesions, and 14 had only one. Wedge resections were performed in the majority of cases. The histological pattern was necrosis and/or fibrosis in 13 patients, teratoma in 11, growing teratoma in 4, active disease in 3 and nodular sarcoidosis in 1 patient. Six of the 32 operated patients relapsed (one of them in the thorax): 4 died of disease, 2 are alive with evolutive disease (AWD); all others are alive with no evidence of disease (NED). Sixteen of the 68 not operated patients died of disease and 2 of other cancers, 4 are AWD; all others (46) have NED. Five of the 43 patients with thoracic CR died of disease; all others (38) have NED. Patients not operated on for residual thoracic disease had respectively 1.6 and 2 RR of relapse and death when compared to patients with surgical exeresis of residual thoracic disease. Conclusions: Thoracic surgery is an important part of the management of patients with post-chemotherapy residual NSGCT masses in the thorax. No significant financial relationships to disclose.

Survival outcome of metastatic adenocarcinoma of esophagogastric junction in the trastuzumab era.

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 117-117
Author(s):  
Yukiya Narita ◽  
Hiroko Hasegawa ◽  
Azusa Komori ◽  
Seiichiro Mitani ◽  
Toshiki Masuishi ◽  
...  
Keyword(s):  
Treatment Outcomes ◽  
Esophagogastric Junction ◽  
Lung Metastases ◽  
Objective Response ◽  
Cancer Center ◽  
Survival Outcomes ◽  
Metastatic Adenocarcinoma ◽  
First Line ◽  
Her2 Positive ◽  
Line Chemotherapy

117 Background: Previous studies have reported no differences in treatment outcomes between metastatic adenocarcinoma esophagogastric junction (AEGJ) and gastric adenocarcinoma (GAC). However, after the approval of trastuzumab (Tmab) for the treatment of metastatic AEGJ and GAC survival outcomes remain unclear. Methods: We retrospectively reviewed clinicopathological characteristics, treatment outcomes, and prognoses of 289 consecutive patients with AEGJ and GAC who received first-line chemotherapy from March 2011, when Tmab was approved in Japan, to December 2013 at Aichi Cancer Center Hospital. Prognostic factors were identified using Cox multivariate regression analysis. IHC3+ or IHC2+/ISH+ tumors were defined as HER2 positive. Results: Of 289 patients, 45 (16%) had AEGJ. Patients with AEGJ were significantly younger with lesser lung metastases than those with GAC. HER2-positive rates in AEGJ tended to be greater than those in GAC, but this difference was not statistically significant (22% vs. 16%; P = 0.35). The rates of platinum doublet therapies were not significantly different (72% vs. 78%; P = 0.47). The objective response rate (ORR) was 27% with AEGJ and 40% with GAC (P = 0.17). The median follow-up duration was 12.1 and 11.9 months, respectively. Progression-free survival was similar for both the groups [hazard ration (HR) = 0.97; P = 0.83), while the median overall survival (OS) period was numerically longer for AEGJ than that for GC (14.7 vs. 12.4 months; HR = 0.99; 95% confidence interval = 0.69–1.39; P = 0.92). In patients with AEGJ, an ECOG performance status of 2 and HER2 negativity were significantly associated with poor prognosis, as estimated by the multivariate analyses of OS. The analyses that were limited to patients treated with Tmab as the first-line chemotherapy revealed no significant differences in ORR and median OS between AEGJ and GAC. Conclusions: Even in the Tmab era, there were no significant differences in survival outcomes between metastatic EGC and GAC.

scholarly journals Can a Cure Be Achieved with Taxane-Based Chemotherapy plus Surgery in Patients with Primary Mediastinal Non-Seminomatous Germ Cell Tumors and Progression or Relapse Despite First-Line Chemotherapy?

Onkologie ◽  
2010 ◽  
Vol 33 (3) ◽  
pp. 119-120
Author(s):  
Vera Miskovska ◽  
Antonin Levy ◽  
Christophe C. Massard ◽  
Marine Gross-Goupil ◽  
Alberto Bossi ◽  
...  
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumors ◽  
First Line ◽  
Line Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document